You just read:

ILUMYA™ (tildrakizumab-asmn) 3-Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis

News provided by

Sun Pharmaceutical Industries Ltd.

Mar 01, 2019, 07:31 ET